Magnesium Acetate

證據等級: L5

預測適應症: 10 個

Magnesium Acetate: From Unregistered Electrolyte Product to Predicted Use in Hypertensive Disorder

One-Sentence Summary

Magnesium acetate (DrugBank DB13996) has no SAHPRA registration in South Africa and no confirmed original indication or mechanism-of-action data on file. The TxGNN model predicts possible efficacy in Hypertensive Disorder, but of the 3 clinical trials and 3 publications currently retrieved, only one trial is even partially relevant to blood pressure and none directly studied magnesium acetate itself — so this remains an early, low-confidence research signal rather than an evidence-backed direction.

Quick Overview

Item	Content
Original Indication	Not available — no SAHPRA/TFDA licenses on record
Predicted New Indication	Hypertensive disorder
TxGNN Prediction Score	97.42%
Evidence Level	L3 (cohort/animal + mechanistic literature; trial evidence largely indirect)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for magnesium acetate is not available. Based on known information, magnesium acetate is the magnesium salt of acetic acid, generally used as an electrolyte/mineral source (e.g., in dialysis fluids and parenteral nutrition preparations); it is not registered for any indication in South Africa, so no formal original-indication text exists for comparison.

Mechanistically, magnesium ions act as natural calcium-channel antagonists that can relax vascular smooth muscle, and animal studies of the acetate moiety (a short-chain fatty acid) report antihypertensive effects mediated via gut microbiota metabolites. This gives a plausible — but only preclinical — biological rationale for exploring a blood-pressure-related indication.

However, the supporting evidence retrieved for this candidate is weak. Of the 3 clinical trials linked to “hypertensive disorder,” only NCT07206524 (magnesium concentration in dialysate and hemodialysis-associated thromboinflammation) is mechanistically related to magnesium and blood pressure regulation — and its endpoint (preventing intradialytic hypotension) points in the opposite clinical direction from treating hypertension. The other two trials (an asthma/DASH-diet study and a steroid-induced glaucoma study) appear to be keyword mismatches on the word “acetate” rather than genuine evidence. The three literature citations are all animal/cohort studies of gut-derived acetate and hypertension programming, not studies of magnesium acetate as a drug.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05251402	Phase 2/3	Active, not recruiting	323	DASH diet trial in uncontrolled asthma; hypertension link is indirect (DASH = “Dietary Approaches to Stop Hypertension”), not a magnesium acetate study. Graded C relevance.
NCT07206524	N/A	Recruiting	15	Pilot study of magnesium concentration in citrate-enriched dialysate and hemodialysis-associated thromboinflammation; relevant to magnesium/hemodynamics but targets prevention of dialysis-related hypotension, not hypertension treatment. Graded B relevance.
NCT00570479	Phase 1	Completed	12	Anecortave acetate for steroid-induced glaucoma; unrelated drug and indication, likely an “acetate” string match. Graded C relevance.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35887270	2022	Animal study	International Journal of Molecular Sciences	Maternal acetate supplementation reversed blood-pressure increases in offspring exposed to minocycline in utero; supports an antihypertensive effect of acetate in a rodent model.
33087738	2020	Cohort/animal model	Scientific Reports	Dietary fibre and its metabolite acetate previously shown to protect against hypertension and heart disease in certain models; gut microbiota modulation did not override genetic predisposition to heart failure.
31295767	2019	Review/mechanistic	Molecular Nutrition & Food Research	Reviews short-chain fatty acid (including acetate) supplementation to prevent maternal high-fructose-diet-induced hypertension programming in offspring.

South Africa Market Information

Magnesium acetate currently has no SAHPRA registrations and is not marketed in South Africa. No product listings, dosage forms, or approved indication text are available for review.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: Regulatory-labeled warnings, contraindications, and drug interaction data for magnesium acetate could not be sourced during this evaluation, which blocks any formal safety pre-assessment for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale:

The drug is unregistered and unmarketed in South Africa, its mechanism of action is unknown, and safety/PI data needed for even a preliminary risk assessment could not be sourced.
The evidence base for the top predicted indication (Hypertensive Disorder) is thin and largely indirect — no trial directly tests magnesium acetate in hypertension, and supporting literature is limited to animal/cohort studies of the acetate moiety in general, not the drug itself.

To proceed, the following is needed:

TFDA/SAHPRA-sourced Professional Information (PI): warnings, contraindications, drug interactions
DrugBank or equivalent mechanism-of-action data for magnesium acetate specifically
Direct clinical or preclinical evidence testing magnesium acetate (not acetate/magnesium generally) in hypertension
Clarification of trial relevance for NCT05251402 and NCT00570479, which currently appear to be keyword-matching artifacts rather than genuine evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.